logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5662.produswest2
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5662.produswest2
Showing 1 - 20 of 207 Items
Showing 1 - 20 of 207 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Using an analogue-digital hybrid clinical data management platform during a two-dose preventive Ebola virus vaccine trial in Goma, the Democratic Republic of the Congo

Brindle HE, Tetsa-Tata D, Edwards T, Choi EML, Kasonia K,  et al.
2025-05-02 • PLOS Global Public Health
2025-05-02 • PLOS Global Public Health

Clinical trials in settings with intermittent or non-existent internet and power connectivity, for example ...

Journal Article
|
Research
Journal Article
|
Review
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Review
Journal Article
|
Short Report
Journal Article
|
Case Report/Series
Journal Article
|
Research
Journal Article
|
Research
Conference Material
|
Abstract
Conference Material
|
Poster
Conference Material
|
Abstract
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Commentary
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Book Chapter

Evaluation of a decentralised model of care on case isolation and patient outcomes during the 2018–20 Ebola outbreak in the Democratic Republic of the Congo: a retrospective observational study

Barks PM, Camacho A, Newport T, Ribeiro F, Ahuka-Mundeke S,  et al.
2025-03-25 • Lancet Global Health
2025-03-25 • Lancet Global Health

Ebola disease: Bridging scientific discoveries and clinical application

Rojek A, Fieggen J, Apiyo P, Caluwaerts S, Fowler RA,  et al.
2024-12-01 • Lancet Infectious Diseases
2024-12-01 • Lancet Infectious Diseases

The west Africa Ebola disease epidemic (2014-16) marked a historic change of course for patient care during emerging infectious disease outbreaks. The epidemic response was a failure ...

rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l’essai proches)

Watson CH, Gsell PS, Hall Y, Camacho A, Riveros X,  et al.
2024-11-07 • BMC Medicine
2024-11-07 • BMC Medicine

BACKGROUND

Zaire Ebolavirus disease (EVD) outbreaks can be controlled using rVSV-ZEBOV vaccination and other public health measures. People in high-risk areas m...

Rapid decision algorithm for patient triage during Ebola outbreaks

Ardiet DL, Nsio J, Komanda G, Coulborn RM, Grellety E,  et al.
2024-11-01 • Emerging Infectious Diseases
2024-11-01 • Emerging Infectious Diseases

The low specificity of Ebola virus disease clinical signs increases the risk for nosocomial transmission to patients and healthcare workers during outbreaks. Reducing this risk requir...

Improving Ebola virus disease outbreak control through targeted post-exposure prophylaxis

Elin Hoffmann Dahl, Prof Placide Mbala, Sylvain Juchet, Prof Abdoulaye Touré, Alice Montoyo,  et al.
2024-09-10 • The Lancet Healthy Longevity
2024-09-10 • The Lancet Healthy Longevity

Evaluation of centralised and decentralised models of care during the 2020 Ebola Virus Disease outbreak in Equateur Province, Democratic Republic of the Congo: A brief report

Lampaert E, Nsio JM, Nair D, Mashako M, De Weggheleire A,  et al.
2024-08-28 • F1000Research
2024-08-28 • F1000Research

BACKGROUND

Tradi...

Effectiveness of rVSV-ZEBOV vaccination during the 2018–20 Ebola virus disease epidemic in the Democratic Republic of the Congo: a retrospective test-negative study

Meakin S, Nsio J, Camacho A, Kitenge R, Coulborn RM,  et al.
2024-08-01 • Lancet Infectious Diseases
2024-08-01 • Lancet Infectious Diseases

BACKRGOUND

The rec...

Immunogenicity of an extended dose interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen in adults and children in the Democratic Republic of the Congo

Choi EM, Kasonia K, Kavunga-Membo H, Mukadi-Bamuleka D, Soumah A,  et al.
2024-07-26 • Vaccines
2024-07-26 • Vaccines

During the 2018–2020 Ebola virus disease outbreak in Democratic Republic of the Congo, a phase 3 trial of the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine (DRC-EB-001) commenced in Goma, wit...

Delivery and safety of a two-dose preventive Ebola virus disease vaccine in pregnant and non-pregnant participants during an outbreak in the Democratic Republic of the Congo

Kavunga-Membo H, Watson-Jones D, Kasonia K, Edwards T, Camacho A,  et al.
2024-07-23 • Vaccines
2024-07-23 • Vaccines

During the 2018–2020 Ebola virus disease (EVD) outbreak, residents in Goma, Democratic Republic of the Congo, were offered a two-dose prophylactic EVD vaccine. This was the first stud...

Effectiveness of rVSV-ZEBOV vaccination during the 10th Ebola virus disease epidemic in the Democratic Republic of the Congo: a retrospective observational analysis

Meakin S
2024-05-23 • Epicentre Scientific Day 2024
2024-05-23 • Epicentre Scientific Day 2024
BACKGROUND
The recombinant vesicular stomatitis virus–Zaire Ebola virus (rVSV-ZEBOV) vaccine is the only vaccine recommended for use to respond to Zaire ebolavirus outbreaks by SAGE....

Unravelling the chains of transmission of the 9th Ebola outbreak in DRC, 2018

Soubrier H, Talla C, Gaye A, Mbala P, Van Herp M,  et al.
2024-05-23 • Epicentre Scientific Day 2024
2024-05-23 • Epicentre Scientific Day 2024

Case fatality risk among individuals vaccinated with rVSVΔG-ZEBOV-GP: a retrospective cohort analysis of patients with confirmed Ebola virus disease in the Democratic Republic of the Congo

Coulborn RM
2024-05-23 • Epicentre Scientific Day 2024
2024-05-23 • Epicentre Scientific Day 2024
BACKGROUND
The rVSVΔG-ZEBOV-GP vaccine constitutes a valuable tool to control Ebola virus disease (EVD) outbreaks. This study aimed to assess the protective effect of the vaccine aga...

Methodological issues of retrospective surveys for measuring mortality of highly clustered diseases: case study of the 2014–16 Ebola outbreak in Bo District, Sierra Leone

Caleo G, Lokuge K, Kardamanidis K, Greig J, Belava J,  et al.
2024-04-25 • Global Health Action
2024-04-25 • Global Health Action
BACKGROUND
There is a lack of empirical data on design effects (DEFF) for mortality rate for highly clustered data such as with Ebola virus disease (EVD), along with a lack of docume...

Perceptions, attitudes, and willingness of healthcare and frontline workers to participate in an Ebola vaccine trial in Uganda

Kimbugwe G, Vatrinet R, Mwanga JA, Kakuru R, Mpeirwe D,  et al.
2024-04-01 • Vaccine
2024-04-01 • Vaccine
BACKGROUND
Understanding the knowledge, perception and attitudes towards Ebola vaccines is an important factor in ensuring future use of these vaccines. A qualitative methods study e...

Individual and household risk factors for Ebola disease among household contacts in Mubende and Kassanda districts, Uganda, 2022

Migamba S, Ardiet DL, Migisha R, Nansikombi HT, Agaba B,  et al.
2024-03-30 • BMC Infectious Diseases
2024-03-30 • BMC Infectious Diseases
BACKGROUND
In 2022, a Sudan virus disease (SVD) outbreak occurred in Uganda, resulting in 142 confirmed cases, most in Mubende and Kassanda districts. We determined risk factors for ...

An oral antiviral for Ebola disease

Sprecher A, Van Herp M
2024-03-15 • Science
2024-03-15 • Science
For those exposed to filovirus, such as Sudan virus and Ebola virus, a new study offers hope.

Factors associated with reliable contact tracing during the 2021 Ebola virus disease outbreak in Guinea

Keita M, Cherif IS, Polonsky JA, Boland ST, Kandako Y,  et al.
2024-02-19 • Journal of Epidemiology and Community Health
2024-02-19 • Journal of Epidemiology and Community Health

BACKGROUND

In 2021, an Ebola virus disease (EVD) outbreak was declared in Guinea, linked to persistent virus from the 2014–2016 West Africa Epidemic. This paper...

Case fatality risk among individuals vaccinated with rVSVΔG-ZEBOV-GP: a retrospective cohort analysis of patients with confirmed Ebola virus disease in the Democratic Republic of the Congo

Coulborn RM, Bastard M, Peyraud N, Gignoux EM, Luquero FJ,  et al.
2024-02-01 • Lancet Infectious Diseases
2024-02-01 • Lancet Infectious Diseases
BACKGROUND
The rVSVΔG-ZEBOV-GP vaccine constitutes a valuable tool to control Ebola virus disease outbreaks. This retrospective cohort study aimed to assess the protective effect of ...

Building partnerships and confronting challenges: Implementation of an ebola virus vaccine clinical study during an outbreak in the Democratic Republic of the Congo

Bausch DG, Kavunga-Membo H, Grais RF, Imbault N, Roberts N,  et al.
2023-12-31 • Nephrology Dialysis Transplantation
2023-12-31 • Nephrology Dialysis Transplantation

Research, especially clinical trials, during outbreaks often poses enormous challenges, and up until very recent times was often considered almost impossible. However, for diseases su...